Palvella Therapeutics

Price & Volume

Stats

52W Range	$12.02-$114.69
Market Cap	$1B
Shares Short	824,522

Financials

Revenue (12 Mos)	$0
Revenue Growth (YoY)	0%
Gross Profit (12 Mos)	$0
Diluted EPS	-$2.92

News

Yahoo Finance • 23 days ago

Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer

Yahoo Finance • 24 days ago

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

Yahoo Finance • 2 months ago

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Yahoo Finance • 2 months ago

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

About

CEO	Mr. Wesley H. Kaupinen
CFO	Mr. Matthew E. Korenberg
Address	125 Strafford Avenue, Wayne, PA, United States, 19087
Sector	Healthcare
Industry	Biotechnology
Full-Time Employees	14